TwitterBiography
Amr R. Hassan, MD, specializes in Hematology and Medical Oncology at Burjeel Hospital, Abu Dhabi. Dr. Amr did his Fellowship and Residency at the University of Massachusetts Medical School. He is a triple Board-Certified Physician by the American Board of Internal Medicine in Internal Medicine, Hematology, and Medical Oncology. He has close to 15 years of clinical experience managing medical oncology disorders and hematologic diseases, both benign and malignant. He has been involved as a principal investigator and a sub-investigator in multiple clinical trials in the USA. He uses the latest treatment regimens and protocols per the American National Comprehensive Cancer Network (NCCN) guidelines. He has been incorporating the latest approved drugs by the American FDA, including targeted chemotherapeutic agents and immunotherapy drugs. He was most recently the Medical Director of The Cancer Treatment Center at Sky Lakes Medical Center in the USA, where he was part of the leadership team in the advancement and progress of this cancer facility.
Amr R. Hassan, MD, specializes in Hematology and Medical Oncology at Burjeel Hospital, Abu Dhabi. Dr. Amr did his Fellowship and Residency at the University of Massachusetts Medical School. He is a triple Board-Certified Physician by the American Board of Internal Medicine in Internal Medicine, Hematology, and Medical Oncology. He has close to 15 years of clinical experience managing medical oncology disorders and hematologic diseases, both benign and malignant. He has been involved as a principal investigator and a sub-investigator in multiple clinical trials in the USA. He uses the latest treatment regimens and protocols per the American National Comprehensive Cancer Network (NCCN) guidelines. He has been incorporating the latest approved drugs by the American FDA, including targeted chemotherapeutic agents and immunotherapy drugs. He was most recently the Medical Director of The Cancer Treatment Center at Sky Lakes Medical Center in the USA, where he was part of the leadership team in the advancement and progress of this cancer facility.
